Answers are grounded in this paper and cite their sources.
Sparse and irregular longitudinal measurements are common in clinical studies but are difficult to incorporate into conventional classifiers without interpolation or substantial feature reduction. We developed an interpretable multiclass likelihood contrast framework for classifying unaligned longitudinal trajectories and evaluated it using simulation experiments and Parkinson's disease motor-UPDRS data. The proposed approach fits class-specific mixed-effects models and classifies each held-out subject according to the largest marginal likelihood, using a quadratic mean trajectory with subject-specific random intercepts and slopes. Performance was assessed using subject-level cross-validation and compared with linear mixed-likelihood classification, functional k -nearest neighbors, random forest, support vector machine, polynomial-feature classification, and grid-based principal component analysis classifiers. In the Parkinson's disease experiment, dense longitudinal histories were used to define three mathematical trajectory phenotypes, after which approximately 90% of observations were masked to evaluate phenotype recovery from sparse records. Despite this substantial sparsification, the proposed model achieved an accuracy of 0.8095, macro-F1 of 0.8160, Matthews correlation coefficient of 0.7107, and macro-area under the receiver operating characteristic curve of 0.9268. Validation and held-out test macro-F1 values were 0.7980 and 0.8160, respectively, suggesting consistent performance across data partitions. These findings demonstrate that multiclass likelihood contrast learning can preserve informative temporal structure in sparse, irregular longitudinal records without reducing individual trajectories to a small number of summary features. The Parkinson's disease findings represent recovery of data-derived trajectory phenotypes rather than prospective clinical prediction or diagnostic validation. Further evaluation in larger independent cohorts with clinically defined outcomes and multimodal longitudinal biomarkers is needed to establish clinical utility.
No takes yet. Share an insight, caveat, or question.
pangeni et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: